×
About 11,620 results

ALLMedicine™ Neuroblastoma Center

Research & Reviews  4,273 results

The cellular prion protein interacts with and promotes the activity of Na,K-ATPases.
https://doi.org/10.1371/journal.pone.0258682
PloS One; Williams D, Mehrabian M et. al.

Dec 1st, 2021 - The prion protein (PrP) is best known for its ability to cause fatal neurodegenerative diseases in humans and animals. Here, we revisited its molecular environment in the brain using a well-developed affinity-capture mass spectrometry workflow tha...

FMRP and MOV10 regulate Dicer1 expression and dendrite development.
https://doi.org/10.1371/journal.pone.0260005
PloS One; Lannom MC, Nielsen J et. al.

Dec 1st, 2021 - Fragile X syndrome results from the loss of expression of the Fragile X Mental Retardation Protein (FMRP). FMRP and RNA helicase Moloney Leukemia virus 10 (MOV10) are important Argonaute (AGO) cofactors for miRNA-mediated translation regulation. W...

Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel norma...
https://doi.org/10.1158/1078-0432.CCR-21-2241
Clinical Cancer Research : an Official Journal of the Ame... Su Y, Luo B et. al.

Dec 1st, 2021 - Anlotinib has achieved good results in clinical trials of a variety of cancers. However, the effects of anlotinib on the tumor microenvironment (TME) and systemic immunity have not been reported. There is an urgent need to identify the underlying ...

A SCN8A variant associated with severe early onset epilepsy and developmental delay: Lo...
https://doi.org/10.1016/j.eplepsyres.2021.106824
Epilepsy Research; Liu Y, Koko M et. al.

Dec 1st, 2021 - SCN8A, encoding the voltage-gated sodium channel subunit NaV1.6, has been associated with a wide spectrum of neuropsychiatric disorders. Missense variants in SCN8A which increase the channel activity can cause a severe developmental and epileptic ...

Risk of developing second malignant neoplasms in patients with neuroblastoma: a populat...
https://doi.org/10.1186/s13014-021-01943-x 10.1097/MPH.0000000000000148 10.1016/j.ejca.2016.11.022 10.1200/JCO.2009.24.8351 10.1002/ijc.11455 10.1002/cncr.11167 10.1093/jnci/djp230 10.1038/bmt.2012.166 10.1038/nrclinonc.2013.41 10.1093/jnci/djq238 10.1002/pbc.21931 10.1002/pbc.25033 10.1016/j.ejca.2016.07.017 10.1097/00043426-200307000-00009 10.1002/pbc.25249
Radiation Oncology (London, England); Zhen H, Guan H et. al.

Nov 29th, 2021 - Neuroblastoma is a common extracranial malignant tumor in children. Its main treatment modality is a combination of chemotherapy, radiotherapy, and surgery. Given the advances in chemotherapy regimens and the widespread use of bone marrow transpla...

see more →

Guidelines  1 results

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marro...
https://doi.org/10.1038/sj.bjc.6605029
British Journal of Cancer; Beiske K, Burchill SA et. al.

Apr 30th, 2009 - Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neuroblastoma. Its accurate and sensitive assessment can facilitate optimal treatment decisions. The International Neuroblastoma Risk Group (INRG) Task...

see more →

Drugs  47 results see all →

Clinicaltrials.gov  155 results

Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).
https://clinicaltrials.gov/ct2/show/NCT05012098

Nov 25th, 2021 - PRECIS Background: Olfactory neuroblastoma (ONB, also known as esthesioneuroblastoma), is a rare malignant neoplasm of the nasal cavity. At diagnosis, ONB is often locally advanced. It tends to invade locally and has high rates of regional spread ...

A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects
https://clinicaltrials.gov/ct2/show/NCT03561259

Nov 24th, 2021 - OPTIMUM (MIBG 2014-01) is a Phase II, Two arm, non-randomized, open-label study of therapeutic 131I-iobenguane (131I-MIBG) as single agent or in combination with Vorinostat for the treatment of neuroblastoma. The study will be conducted in male an...

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma
https://clinicaltrials.gov/ct2/show/NCT04724369

Nov 15th, 2021 - This is a prospective, Phase 3, multi-center, open-label study designed to assess the use of 18F-mFBG PET imaging in subjects with known or presumed neuroblastoma. Eligible participants will have either histopathologically established diagnosis of...

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
https://clinicaltrials.gov/ct2/show/NCT05061017

Nov 9th, 2021 - Nivolumab is approved by the FDA for the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of head/neck, urothelial carcinoma, MSI-H...

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young ...
https://clinicaltrials.gov/ct2/show/NCT04029688

Nov 3rd, 2021 - This is a Phase I/II, multicenter, open-label, multi-arm study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin, administered as a single agent or in combination with chemotherapy or venetocl...

see more →

News  169 results

Treating ALK-Mutant and KRAS G12C–Mutant NSCLC
https://www.onclive.com/view/treating-alk-mutant-and-kras-g12c-mutant-nsclc

Nov 16th, 2021 - John V. Heymach, MD, PhD: One other disease space where we’ve had spectacular successes recently in terms of wonderful drugs that have come along—very active drugs—has been ALK [anaplastic lymphoma kinase inhibitors]. We’ve got a lot of fantastic ...

BCL-2 Inhibitors May Provide Avenue of Attack Against High-Risk Neuroblastoma
https://www.onclive.com/view/bcl-2-inhibitors-may-provide-avenue-of-attack-against-high-risk-neuroblastoma

Oct 6th, 2021 - Anthony Faber, PhD Member, Developmental Therapeutics Research Program Virginia Commonwealth University (VCU) Massey Cancer Center Assistant Professor, Philips Institute for Oral Health Research, VCU School of Dentistry Madhu Gowda, MD ...

University of Wisconsin Carbone Cancer Center: A Tradition of Comprehensive, Multidisciplinary Care
https://www.onclive.com/view/university-of-wisconsin-carbone-cancer-center-a-tradition-of-comprehensive-multidisciplinary-care

Oct 6th, 2021 - University of Wisconsin Carbone Cancer Center Recognized throughout the nation as one of the leading innovators in cancer research, patient care, and community outreach, the University of Wisconsin Carbone Cancer Center (UWCCC) in Madison has it...

Persistent Development of WEE1 Pathway Inhibitors Begins to Pay Off
https://www.onclive.com/view/persistent-development-of-wee1-pathway-inhibitors-begins-to-pay-off

Aug 25th, 2021 - WEE1 is a key regulator of the cell cycle that has been a target of cancer drug discovery efforts for more than a decade. The lead novel candidate, the WEE1 inhibitor adavosertib (AZD1775), has been tested in more than 50 completed or ongoing clin...

ALK Inhibitor Success Prompts Search for a Role Beyond NSCLC
https://www.onclive.com/view/alk-inhibitor-success-prompts-search-for-a-role-beyond-nsclc

Aug 25th, 2021 - The rapid development of novel agents directed at anaplastic lymphoma kinase (ALK) gene fusions has emerged as one of the success stories of the targeted therapy era in non–small cell lung cancer (NSCLC).1,2 However, oncogenic activation of ALK, t...

see more →

Patient Education  3 results see all →